Search
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Partnering Interests in Retinal Health
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Five ways to include more diversity in clinical trials
Animal Health Partnering Interests Infectious Diseases May 2024 CORP
Animal Health Partnering Interests Pain & Mobility May 2024 CORP
Animal Health Partnering Interests Immunology & Inflammation May 2024 CORP
Partnering_in_Retinal Health
2024 MORE GREEN infographic - Environmental Stewardship at Boehringer Ingelheim
Partnering_In_PAIN_0.pdf
Partnering_In_INFECTIOUS_1.pdf
Defining underserved communities_Infographic_230627.pdf
Partnering in Infectious Diseases MAY 2024 CORP_0.pdf
Supplier Training Deck - Invoice
Partnering with Boehringer Ingelheim MAY 2023 Corp
Defining underserved communities_Infographic_230627.pdf
Infographic_Defining underserved communities_230627.pdf
Partnering in Immunology & Inflammation MAY 2024 CORP_0.pdf
Partnering in Pain & Mobility MAY 2024 CORP_0.pdf
Boehringer_Ingelheim_auf_einen_Blick_2018.pdf
Boehringer Ingelheim Animal Health Business Unit Factsheet_2.pdf
WISDOM_Infographic_Final_Print Ready.pdf
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.